Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6NUJ

HIV-1 Integrase Catalytic Core Domain Complexed with Allosteric Inhibitor BI-224436

Summary for 6NUJ
Entry DOI10.2210/pdb6nuj/pdb
DescriptorIntegrase, (2S)-tert-butoxy[4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl]acetic acid (3 entities in total)
Functional Keywordshiv, integrase, inhibitor, allosteric, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological sourceHuman immunodeficiency virus 1
Total number of polymer chains1
Total formula weight18886.19
Authors
Lindenberger, J.J.,Kvaratskhelia, M. (deposition date: 2019-02-01, release date: 2019-12-11, Last modification date: 2024-10-23)
Primary citationKoneru, P.C.,Francis, A.C.,Deng, N.,Rebensburg, S.V.,Hoyte, A.C.,Lindenberger, J.,Adu-Ampratwum, D.,Larue, R.C.,Wempe, M.F.,Engelman, A.N.,Lyumkis, D.,Fuchs, J.R.,Levy, R.M.,Melikyan, G.B.,Kvaratskhelia, M.
HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors.
Elife, 8:-, 2019
Cited by
PubMed Abstract: Allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are a promising new class of antiretroviral agents that disrupt proper viral maturation by inducing hyper-multimerization of IN. Here we show that lead pyridine-based ALLINI KF116 exhibits striking selectivity for IN tetramers versus lower order protein oligomers. IN structural features that are essential for its functional tetramerization and HIV-1 replication are also critically important for KF116 mediated higher-order IN multimerization. Live cell imaging of single viral particles revealed that KF116 treatment during virion production compromises the tight association of IN with capsid cores during subsequent infection of target cells. We have synthesized the highly active (-)-KF116 enantiomer, which displayed EC of ~7 nM against wild type HIV-1 and ~10 fold higher, sub-nM activity against a clinically relevant dolutegravir resistant mutant virus suggesting potential clinical benefits for complementing dolutegravir therapy with pyridine-based ALLINIs.
PubMed: 31120420
DOI: 10.7554/eLife.46344
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.10002700303 Å)
Structure validation

247947

PDB entries from 2026-01-21

PDB statisticsPDBj update infoContact PDBjnumon